BioCentury | Dec 4, 2020
Finance

Dec. 3 Quick Takes: Israeli digital health firm closes $170M fund; plus BioAge, newco Rubedo, Portal Innovations, OliX

OTV closes $170M fundIsrael-based digital health VC OTV has changed its name from Olive Tree Ventures and closed a $170 million fund. The firm also said it hired Jose Antonio Urrutia Rivas, who was an associate...
BioCentury | Nov 20, 2020
Product Development

Phase III COVID-19 vaccine data kick-start next phase: mapping efficacy to antibody levels

Efficacy data from the first two Phase III trials of COVID-19 vaccines shattered expectations and validated mRNA as a vaccine modality. The findings also mark the start of the search for correlates of protection. An...
BioCentury | Oct 28, 2020
Deals

Out of the Arena: With $56M round, spinout Longboard to house trio of neuroscience programs

With $56 million in fresh funding from a crossover syndicate, newly launched Longboard will develop three neuroscience programs spun out from Arena that share familiar targets with therapies previously developed by the parent company. The...
BioCentury | Oct 23, 2020
Product Development

What’s next for targeted protein degradation

As targeted protein degradation grows up, the field is going after harder targets and new mechanisms of action. Over the last year, a series of Phase I/II readouts from front-runner Arvinas Inc. (NASDAQ:ARVN),...
BioCentury | Oct 21, 2020
Product Development

UCSF’s virus-host protein interaction maps ID targets for COVID-19, future coronaviruses

A UCSF-led team has identified host pathways that could inform development of countermeasures against future coronaviruses, as they interact with multiple coronaviruses that recently made the leap...
BioCentury | Oct 19, 2020
Finance

How Nimbus’ focus on internal pipeline could point to long-awaited exit

With a new $60 million crossover round and an internal pipeline moving through the clinic, computational chemistry company Nimbus may be nearing a liquidity event for investors who have stuck with the...
BioCentury | Oct 17, 2020
Product Development

How the PanCAN master protocol could promote innovation in pancreatic cancer

The motivation for launching the first adaptive platform trial in pancreatic cancer is to stimulate therapeutic innovation in an indication sorely in need of new ideas. The hope of the non-profit...
BioCentury | Oct 13, 2020
Product Development

CTTI encourages master protocol design with new road map

By providing resources for patient organizations, a new master protocols road map created by the Clinical Trials Transformation Initiative could encourage broader adoption of the trial structure. CTTI...
BioCentury | Oct 9, 2020
Deals

Oct. 8 Quick Takes: Kronos ready for NASDAQ debut; plus Sensei, TCRyption, Jazz, Pfizer-Opko and Moderna

Kronos raises $250M in NASDAQ IPOLook for shares of Kronos Bio Inc. (NASDAQ:KRON) to begin trading on Friday after the company raised $250 million in an IPO. The listing completes a busy few months for...
BioCentury | Oct 8, 2020
Product Development

Mapping opportunities for China’s early cancer detection boom

As investor enthusiasm for blood-based cancer screening soars in the wake of Grail’s $8 billion acquisition,  much of the activity is taking place in China, where a short list of dominant cancers, out-of-pocket spending habits...
Items per page:
1 - 10 of 2154